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Dengue	  virus	  is	  the	  leading	  cause	  of	  morbidity	  and	  mortality	  among	  mosquito-­‐borne	  
viruses	  globally.	  	  There	  are	  four	  Dengue	  serotypes;	  immunity	  to	  one	  serotype	  provides	  
protective	  immunity	  to	  that	  serotype	  but	  increases	  the	  risk	  of	  severe	  disease	  upon	  infection	  
with	  a	  second	  serotype.	  Dengue	  virus,	  like	  all	  Flaviviruses,	  utilizes	  class	  II	  fusion	  proteins	  to	  
gain	  entry	  into	  the	  host	  cytoplasm.	  The	  fusion	  loop,	  which	  is	  responsible	  for	  viral-­‐host	  
fusion,	  lies	  within	  the	  envelope	  (E)	  glycoprotein	  and	  has	  nearly	  100%	  amino	  acid	  identity	  
among	  all	  Flaviviruses.	  Two	  anti-­‐Dengue	  virus	  human	  monoclonal	  antibodies	  (hMAbs),	  1.6D	  
and	  D11C,	  were	  isolated	  from	  Dengue	  infected	  patients,	  and	  determined	  to	  target	  the	  
fusion	  loop	  (1).	  These	  antibodies	  not	  only	  neutralize	  all	  four	  Dengue	  serotypes,	  but	  also	  
have	  broadly	  anti-­‐Flavivirus	  cross-­‐neutralizing	  capabilities	  in	  mammalian	  cells.	  While	  these	  
antibodies	  could	  contribute	  to	  antibody	  enhancement	  of	  infection	  in	  humans,	  their	  
neutralizing	  capabilities	  could	  be	  employed	  within	  a	  transgenic	  mosquito	  line	  serving	  as	  a	  
novel	  control	  strategy	  to	  block	  arbovirus	  transmission.	  
Methods	  
The	  neutralization	  capacity	  of	  purified	  hMAbs	  1.6D	  and	  D11C	  were	  tested	  against	  Dengue	  
virus	  2,	  3,	  and	  4,	  and	  Zika	  virus	  in	  C6/36	  Aedes	  albopictus	  mosquito	  cells	  using	  a	  
Fluorescent	  Focal	  Unit	  Assay.	  Additionally,	  the	  inhibitory	  capacity	  of	  1.6D	  was	  evaluated	  in	  
Aedes	  aegypti	  mosquitoes.	  Mosquitoes	  were	  intrathoracically	  inoculated	  with	  Dengue	  virus	  
2	  and	  either	  1.6D	  or	  C11,	  a	  hMAb	  anti-­‐Gp41	  HIV1,	  used	  as	  an	  antibody	  control.	  Viral	  RNA	  
was	  extracted	  from	  mosquitoes	  two	  and	  four	  days	  post	  infection	  and	  viral	  loads	  were	  




Antibodies	  1.6D	  and	  D11C	  reduced	  viral	  infections	  in	  C6/36	  cells	  for	  all	  Dengue	  serotypes	  
tested,	  in	  a	  dose-­‐dependent	  manner.	  Both	  antibodies	  inhibited	  50%	  of	  each	  Dengue	  virus	  at	  
less	  than	  2µg/ml,	  comparable	  to	  what	  was	  reported	  in	  mammalian	  cells,	  although	  
inhibition	  was	  not	  observed	  for	  Zika	  virus.	  Dengue	  2	  viral	  loads	  were	  significantly	  
decreased	  in	  Aedes	  aegypti	  mosquitoes	  treated	  with	  1.6D	  compared	  to	  the	  control	  antibody.	  
Conclusion	  
This	  study	  demonstrates	  the	  efficacy	  of	  broadly	  neutralizing	  human	  antibodies	  to	  reduce	  
Flavivirus	  infections	  in	  mosquitoes.	  Additional	  research	  should	  assess	  the	  efficacy	  of	  this	  
approach	  in	  a	  biologically	  relevant	  context	  and	  determine	  the	  impact	  of	  this	  strategy	  to	  


























Epidemiology	  and	  Burden	  of	  Disease	  
Dengue	  virus	  is	  transmitted	  by	  Aedes	  mosquitoes	  in	  tropical	  and	  sub-­‐tropical	  climates	  
globally.	  There	  are	  an	  estimated	  390	  million	  cases	  of	  Dengue	  virus	  infections	  per	  year	  
including	  about	  100	  million	  cases	  of	  dengue	  fever	  and	  21,000	  deaths	  (2).	  Dengue	  fever	  is	  a	  
flu-­‐like	  illness,	  which	  can	  be	  fatal	  when	  it	  progresses	  to	  dengue	  hemorrhagic	  fever	  or	  
dengue	  shock	  syndrome.	  There	  are	  four	  dengue	  virus	  serotypes	  (DENV1,	  DENV2,	  DENV3,	  
DENV4);	  infection	  with	  one	  provides	  sterilizing	  immunity	  from	  that	  serotype	  but	  only	  
partial	  protection	  to	  other	  serotypes	  with	  subsequent	  infections	  having	  increased	  risk	  of	  
severe	  manifestations	  (3).	  	  
	  
Currently	  there	  is	  no	  specific	  treatment	  for	  dengue	  viral	  infections.	  Hospitalization	  and	  
fluid	  replacement	  therapy	  can	  provide	  effective	  support	  for	  the	  symptoms	  of	  severe	  disease	  
(4).	  Phase	  III	  clinical	  trials	  have	  concluded	  for	  a	  tetravalent	  vaccine	  developed	  by	  Sanofi-­‐
Pasteur.	  While	  promising,	  vaccine	  efficacy	  was	  only	  35-­‐80%	  depending	  on	  the	  dengue	  
serotype.	  It	  is	  not	  recommended	  for	  children	  under	  9	  years	  old	  as	  it	  has	  been	  shown	  to	  
increase	  the	  severity	  of	  disease	  in	  subsequent	  infections	  (2).	  
	  
In	  addition	  to	  the	  four	  Dengue	  serotypes,	  other	  notable	  mosquito-­‐borne	  Flaviviruses	  cause	  
significant	  morbidity	  and	  mortality	  globally.	  Yellow	  Fever	  virus	  (YFV),	  also	  transmitted	  by	  
Aedes	  mosquitoes,	  infects	  an	  estimated	  100,000	  people	  causing	  60,000	  deaths	  per	  year	  in	  
Africa	  and	  Latin	  America	  (5).	  An	  effective	  vaccine	  is	  available	  but	  does	  not	  always	  reach	  the	  
populations	  with	  the	  greatest	  need	  as	  evidenced	  by	  an	  ongoing	  outbreak	  in	  Angola	  that	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started	  in	  December	  2015	  and	  includes	  1,132	  suspected	  or	  confirmed	  cases	  and	  168	  deaths	  
(6).	  Zika	  virus	  (ZIKV),	  also	  transmitted	  by	  Aedes	  mosquitoes,	  spread	  out	  of	  Africa	  and	  Asia,	  
caused	  epidemics	  in	  the	  Pacific	  in	  2007,	  and	  has	  now	  spread	  to	  the	  majority	  of	  countries	  in	  
Central	  and	  South	  America.	  Zika	  is	  typically	  associated	  with	  minor	  disease	  in	  adults	  but	  is	  
being	  investigated	  as	  a	  causative	  agent	  of	  microcephaly	  and	  Guillain-­‐Barré	  syndrome,	  
among	  others	  (7).	  West	  Nile	  Virus	  (WNV),	  which	  is	  transmitted	  by	  Culex	  mosquitoes,	  is	  
found	  in	  Asia,	  Africa,	  the	  Middle	  East,	  and	  since	  1999	  North	  America.	  While	  birds	  are	  the	  
reservoir	  host,	  humans	  can	  become	  infected	  through	  the	  bite	  of	  an	  infected	  mosquito.	  
Approximately	  80%	  of	  infected	  people	  remain	  asymptomatic.	  However,	  in	  20%	  of	  infected	  
individuals	  disease	  ranges	  from	  fever,	  headache	  and	  vomiting	  to	  a	  more	  severe	  
neuroinvasive	  disease	  that	  can	  include	  coma,	  muscle	  weakness,	  and	  paralysis.	  No	  vaccine	  
or	  specific	  treatment	  is	  available	  (8).	  
	  
Viral	  Structure	  and	  Function	  
Dengue,	  Yellow	  Fever,	  Zika	  and	  West	  Nile	  viruses	  are	  all	  members	  of	  the	  Flavivirus	  genus;	  a	  
genera	  that	  includes	  over	  70	  viruses.	  Flaviviruses	  are	  single-­‐stranded	  positive-­‐sense	  RNA	  
viruses	  approximately	  10.8kb	  in	  length,	  comprising	  a	  single	  open	  reading	  frame	  that	  
encodes	  three	  structural	  proteins:	  capsid	  (C),	  membrane	  (prM	  is	  precursor	  to	  M),	  and	  
envelope	  (E),	  and	  seven	  additional	  non-­‐structural	  proteins	  for	  replication	  and	  transmission	  
(Figure	  1A)(9).	  The	  genome	  is	  packaged	  into	  a	  capsid	  protein,	  surrounded	  by	  a	  host-­‐
derived	  lipid	  bilayer,	  and	  further	  encased	  by	  180	  copies	  of	  two	  glycoproteins	  (prM	  and	  E).	  
The	  E	  protein	  is	  responsible	  for	  receptor-­‐binding	  and	  fusion	  (10).	  	  After	  the	  E	  protein	  binds	  
the	  cell	  receptor	  the	  virus	  is	  internalized	  in	  an	  endosome	  and	  the	  pH	  is	  lowered	  triggering	  a	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conformational	  change	  that	  exposes	  the	  fusion	  loops	  of	  each	  of	  the	  E	  monomers.	  The	  fusion	  
loops	  penetrate	  partway	  through	  the	  host	  membrane	  causing	  the	  fusion	  protein	  monomers	  
to	  collect	  into	  trimers.	  Once	  in	  this	  conformational	  shape	  there	  is	  a	  build	  up	  of	  energy	  that	  
is	  released	  when	  the	  fusion	  protein	  folds	  back	  on	  itself	  bringing	  the	  fusion	  loop	  (inserted	  in	  
the	  host	  membrane)	  towards	  the	  fusion	  protein	  anchor	  (inserted	  in	  the	  viral	  membrane)	  
close	  together	  until	  fusion	  occurs	  (11).	  	  
	  
The	  fusion	  process	  uses	  class	  II	  fusion	  proteins	  in	  order	  to	  fuse	  the	  viral	  membrane	  and	  
host	  cell	  membrane	  and	  deliver	  the	  viral	  genome	  into	  the	  host	  cytoplasm.	  It	  is	  vital	  for	  
virus	  entry	  and	  eventual	  replication.	  The	  essential	  protein	  sequences	  and	  structures	  are	  
conserved	  among	  Flaviviruses	  (11).	  However,	  structural	  analysis	  of	  different	  Dengue	  
serotypes	  suggests	  that	  there	  are	  differences	  in	  the	  distribution	  of	  electric	  charge	  across	  
the	  virus	  surface,	  which	  impacts	  host	  cell	  receptor	  binding.	  There	  are	  also	  differences	  in	  the	  
amino	  acid	  interactions	  between	  the	  E	  proteins	  and	  the	  membrane	  proteins	  that	  are	  at	  the	  
virus	  surface	  (12).	  Furthermore,	  the	  virus	  structure	  changes	  throughout	  the	  infection	  cycle,	  
and	  changes	  in	  temperature	  can	  affect	  the	  exposure	  of	  structural	  epitopes	  that	  are	  bound	  
by	  antibodies	  (12,	  13).	  	  The	  fusion-­‐loop	  of	  WNV	  was	  identified	  as	  a	  region	  that	  had	  variable	  
accessibility	  to	  antibodies.	  Neutralization	  with	  a	  fusion-­‐loop	  binding	  antibody	  was	  
dependent	  on	  time	  and	  temperature.	  Because	  the	  virus	  structure	  is	  dynamic,	  given	  time,	  
antibodies	  could	  inhibit	  infection	  despite	  binding	  epitopes	  that	  are	  not	  constantly	  exposed	  
(14).	  Additionally,	  there	  is	  some	  evidence	  that	  the	  virus	  structure	  changes	  when	  infecting	  a	  
vector	  or	  mammalian	  host.	  The	  structure	  of	  DENV	  was	  determined	  to	  change	  when	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incubated	  at	  28°C	  compared	  to	  37°C,	  the	  temperature	  of	  mosquitoes	  and	  humans	  
respectively	  (2,	  12,	  15,	  16).	  
	  
Broadly	  Neutralizing	  Antibodies	  
The	  E	  protein	  is	  well	  conserved	  with	  about	  40%	  amino	  acid	  identity	  within	  the	  Flavivirus	  
genus.	  Mosquito-­‐borne	  Flaviviruses	  are	  even	  more	  closely	  related	  to	  one	  another	  than	  to	  
tick-­‐borne	  or	  Flaviviruses	  not	  transmitted	  by	  a	  vector	  (Figure	  1B)(10).	  But	  within	  the	  
fusion	  loop	  (amino	  acid	  residues	  98-­‐110	  of	  the	  E	  protein)	  there	  is	  near	  100%	  amino	  acid	  
identity.	  There	  have	  been	  frequent	  reports	  of	  cross-­‐reactive	  antibodies	  that	  bind	  the	  fusion	  
loop,	  but	  only	  a	  few	  studies	  have	  reported	  characterizing	  antibodies	  that	  are	  cross-­‐reactive	  
and	  strongly	  neutralizing	  (1,	  2,	  17-­‐23).	  Characterization	  of	  these	  antibodies	  and	  further	  
development	  is	  being	  pursued	  for	  therapeutic	  purposes.	  However,	  poorly	  neutralizing	  
antibodies	  may	  contribute	  to	  Antibody-­‐dependent	  enhancement	  (ADE)	  of	  dengue	  
hemorrhagic	  fever	  through	  enhanced	  infection	  of	  macrophage	  cells	  (2,	  12,	  21).	  
Additionally,	  research	  suggests	  that	  human	  neutralizing	  antibodies	  typically	  recognize	  
quaternary	  structure	  that	  requires	  intact	  virus	  rather	  than	  a	  recombinant	  protein	  that	  
might	  be	  achieved	  in	  a	  vaccine	  (2).	  The	  importance	  of	  quaternary	  structure	  may	  explain	  
why	  antibodies	  that	  are	  mapped	  to	  a	  highly	  conserved	  amino	  acid	  sequence,	  such	  as	  the	  
fusion	  loop,	  are	  not	  necessarily	  cross-­‐reactive	  or	  cross	  neutralizing.	  
	  
Human	  antibodies	  that	  neutralize	  all	  four	  Dengue	  serotypes	  and	  are	  active	  against	  other	  
Flaviviruses	  have	  previously	  been	  characterized.	  Costin	  et	  al.	  (1)	  determined	  that	  two	  
related	  broadly	  neutralizing	  human	  monoclonal	  antibodies	  1.6D	  and	  D11C	  both	  bound	  to	  a	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well	  conserved	  region	  of	  the	  E	  protein	  fusion	  loop,	  specifically	  W101	  and	  G109	  (Figure	  1C).	  
Antibody	  1.6D	  was	  isolated	  from	  a	  patient’s	  blood	  sample	  3	  months	  after	  an	  infection	  
acquired	  in	  Jamaica	  of	  an	  unknown	  Dengue	  serotype.	  The	  patient	  reported	  symptoms	  
including	  fever,	  headache,	  retro-­‐orbital	  pain,	  and	  blood	  in	  sputum.	  A	  molecular	  clone	  was	  
constructed	  from	  stimulated	  peripheral	  blood	  mononuclear	  cells	  (PBMCs).	  Antibody	  D11C	  
was	  isolated	  from	  a	  patient’s	  blood	  sample	  4	  weeks	  after	  recovering	  from	  a	  Dengue	  
infection	  acquired	  in	  Singapore	  that	  was	  determined	  to	  be	  a	  secondary	  Dengue	  infection.	  A	  
molecular	  clone	  of	  D11C	  was	  produced	  by	  Epstein-­‐Barr	  virus	  transformation	  of	  B	  cells.	  
Both	  antibodies	  were	  grown	  in	  PBMCs	  and	  purified	  by	  protein	  A	  affinity	  chromatography.	  
They	  are	  made	  up	  of	  IgG1	  heavy	  chains	  and	  kappa	  light	  chains.	  In	  addition	  to	  neutralizing	  
all	  four	  Dengue	  serotypes	  in	  mammalian	  cells,	  both	  1.6D	  and	  D11C	  were	  shown	  to	  
effectively	  neutralize	  two	  related	  Flaviviruses,	  WNV	  and	  YFV.	  High	  affinity	  to	  the	  fusion	  
loop	  inhibited	  fusion	  of	  the	  virus	  membrane	  and	  human	  cell	  endosome	  membrane.	  It	  was	  
also	  demonstrated	  that	  these	  antibodies	  could	  contribute	  to	  ADE	  at	  subneutralizing	  
concentrations	  (1).	  
	  
Mosquito	  Control	  Strategies	  
Vector	  control	  is	  a	  widely	  utilized	  method	  to	  block	  transmission	  of	  mosquito-­‐borne	  
diseases.	  There	  have	  been	  prior	  successes,	  such	  as	  for	  malaria	  control,	  utilizing	  insecticide-­‐
treated	  bed	  nets	  and	  indoor	  residual	  spraying.	  However,	  chemical	  tolerance	  and	  resistance	  
threatens	  progress	  of	  mosquito-­‐borne	  infection	  control	  (24-­‐26).	  New	  strategies	  to	  
manipulate	  and	  control	  mosquitoes	  are	  under	  development	  and	  field	  studies	  are	  already	  
showing	  promise.	  Transgenic	  Anopheles	  mosquitoes	  were	  created	  that	  express	  proteins	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and	  human	  antibodies	  that	  inhibit	  malaria	  transmission	  (27-­‐29).	  	  Furthermore,	  mosquito	  
midgut	  microbiota	  have	  been	  manipulated	  to	  express	  and	  secrete	  anti-­‐Plasmodium	  effector	  
proteins	  that	  decrease	  the	  development	  of	  parasites	  (30).	  It	  was	  shown	  that	  the	  Aedes	  
microbiota	  is	  important	  for	  DENV	  infection.	  The	  presence	  of	  Wolbachia	  bacteria	  makes	  
Aedes	  aegypti	  resistant	  to	  Dengue	  infections	  (31).	  Sterilized	  transgenic	  Aedes	  aegypti	  
mosquitoes	  have	  been	  tested	  at	  field	  sites	  as	  a	  new	  vector	  control	  measure	  to	  decrease	  
mosquito	  populations	  (32,	  33).	  Additionally,	  a	  transgenic	  Aedes	  aegypti	  line	  has	  been	  
created	  that	  expresses	  an	  inverted-­‐repeat	  RNA	  in	  the	  mosquito	  midgut	  that	  is	  resistant	  to	  
DENV2	  infections	  (34).	  	  
	  
Despite	  the	  advancement	  of	  technology	  to	  create	  transgenic	  mosquitoes,	  the	  plethora	  of	  
research	  on	  anti-­‐dengue	  human	  antibodies,	  and	  the	  unchecked	  threat	  of	  Dengue	  globally,	  
there	  is	  no	  published	  research	  on	  the	  capacity	  of	  human	  antibodies	  to	  prevent	  DENV	  
infections	  in	  mosquitoes.	  This	  study	  seeks	  to	  characterize	  the	  capacity	  of	  broadly	  cross-­‐
neutralizing	  anti-­‐dengue	  virus	  antibodies	  (1.6D	  and	  D11C)	  to	  inhibit	  Flavivirus	  infections	  of	  
mosquitoes.	  Development	  of	  this	  strategy	  could	  provide	  a	  targeted	  approach	  to	  decrease	  
the	  burden	  of	  mosquito-­‐borne	  viruses.	  The	  antibodies	  tested	  hold	  the	  potential	  to	  prevent	  
transmission	  of	  all	  Dengue	  virus	  serotypes	  and	  other	  mosquito	  transmitted	  Flaviviruses,	  











MATERIALS	  AND	  METHODS	  
	  
Phylogenetic	  Tree	  
A	  phylogenetic	  tree	  was	  generated	  on	  MegAlign	  by	  DNASTAR®	  Software	  for	  Life	  Sciences	  
(Madison,	  WI).	  A	  panel	  of	  Flavivirus	  E	  protein	  nucleotide	  sequences	  were	  downloaded	  from	  
GenBank.	  Viruses	  (accession	  numbers)	  include:	  Dengue	  1	  (KC741442.1,	  AB624554.1,	  
KJ415098.1),	  Dengue	  2	  (FJ606704.1,	  AB545874.1,	  AB545873.1),	  Dengue	  3	  (EU617038.1,	  
GQ357889.1,	  FJ606712.1),	  Dengue	  4	  (AY786201.1,	  AY786200.1,	  AY786202.1),	  Yellow	  
Fever	  (U23580.1,	  U23577.1,	  U23578.1),	  Zika	  (KJ634273.1),	  West	  Nile	  (AF459403.3,	  
JX442282.1,	  DQ823150.1),	  Tick-­‐Borne	  Encephalitis	  Virus	  (TBEV)	  (GQ845440.1).	  TBEV	  is	  a	  
tick-­‐borne	  Flavivirus.	  Alignment	  was	  performed	  by	  Clustal	  W	  method	  and	  phylogenetic	  tree	  
was	  constructed	  using	  1000	  Bootstrap	  trials,	  seed	  111.	  Scale	  is	  percentage	  of	  genetic	  
difference.	  	  
	  
Cells	  and	  Viruses	  
C6/36	  Aedes	  albopictus	  mosquito	  cells	  were	  used	  in	  Fluorescent	  Focus	  Unit	  (FFU)	  assays	  
and	  to	  grow	  virus	  stocks.	  Vero	  (African	  green	  monkey	  kidney	  epithelial)	  cells	  were	  used	  to	  
propagate	  and	  increase	  viral	  titers.	  Cells	  were	  maintained	  in	  complete	  growth	  media,	  
containing	  10%	  Fetal	  Bovine	  Serum	  (FBS),	  0.28%	  Sodium	  Bicarbonate,	  1%	  L-­‐glutamine,	  
1%	  Penicillin/	  Streptomycin	  Antibiotic,	  1%	  Non-­‐essential	  amino	  acids.	  C6/36	  cells	  were	  
incubated	  at	  28°C,	  Vero	  cells	  at	  37°C,	  with	  5%	  CO2.	  Viruses	  (see	  Table	  1)	  were	  grown	  
approximately	  one	  week	  in	  cells;	  aliquots	  were	  centrifuged	  at	  1500rpm	  for	  5	  minutes	  and	  
then	  stored	  in	  -­‐80°C	  until	  use	  in	  experiments.	  Viral	  concentrations	  were	  estimated	  using	  




Fluorescent	  Focus	  Unit	  (FFU)	  Assay	  
FFU	  Assays	  were	  carried	  out	  in	  C6/36	  cells	  as	  described	  previously	  (35).	  One	  day	  prior	  to	  
infection	  0.5x106	  cells	  per	  well	  were	  seeded	  into	  Lab-­‐Tek	  II	  4-­‐chamber	  glass	  slides,	  
ThermoScientific	  (Rochester,	  NY).	  Cells	  were	  infected	  with	  serial	  dilutions	  of	  virus	  stock	  in	  
complete	  media,	  loading	  150μL	  per	  well,	  and	  incubated	  for	  1	  hour	  shaking	  gently	  by	  hand	  
about	  four	  times	  per	  hour.	  Virus	  media	  solution	  was	  removed	  and	  750μL	  of	  5%	  
Methylcellulose	  in	  5%	  FBS	  complete	  media	  was	  added	  per	  well.	  Cells	  were	  incubated	  for	  3	  
days	  at	  28°C.	  After	  3	  days	  Methylcellulose	  solution	  was	  removed,	  500μL	  of	  sterile	  PBS	  was	  
added	  per	  well	  and	  placed	  on	  ice	  for	  5	  minutes.	  PBS	  was	  removed;	  cells	  were	  fixed	  by	  
adding	  500μL	  ice	  cold	  100%	  Methanol	  per	  well	  and	  incubated	  for	  10	  minutes	  at	  -­‐20°C.	  
Methanol	  was	  then	  removed	  and	  replaced	  with	  500μL	  Permeabilization	  buffer	  (0.3%	  
Triton	  in	  PBS)	  for	  about	  10	  minutes	  at	  room	  temperature.	  Buffer	  was	  removed	  and	  
replaced	  with	  500μL	  Blocking	  buffer	  (5%BSA,	  0.1%Tween	  in	  PBS)	  and	  incubated	  for	  30	  
minutes	  at	  room	  temperature	  on	  shaker,	  5rpm.	  Next	  cells	  were	  stained	  with	  the	  primary	  
antibody	  PierceTM	  FlaviVs	  Envelope	  Antibody	  (FE1),	  Thermo	  Scientific	  Prod	  #MA1-­‐71258,	  
1:100	  in	  Blocking	  buffer,	  100μL	  per	  well.	  Cells	  were	  incubated	  for	  1	  hour	  at	  room	  
temperature	  on	  shaker,	  5rpm.	  Cells	  were	  washed	  three	  times	  with	  500μL	  per	  well	  
0.1%Tween	  in	  PBS	  for	  5-­‐10	  minutes	  per	  wash.	  Cells	  were	  stained	  with	  secondary	  antibody	  
Alexa	  Fluor	  488	  goat	  anti-­‐mouse,	  Life	  Technologies,	  1:200	  in	  Blocking	  buffer,	  100μL	  per	  
well.	  Cells	  were	  incubated	  for	  1	  hour,	  room	  temperature	  on	  shaker,	  5rpm.	  Cells	  were	  again	  
washed	  three	  times	  with	  500μL	  per	  well	  0.1%Tween	  in	  PBS	  for	  5-­‐10	  minutes	  per	  wash.	  All	  
liquid	  was	  removed	  from	  wells,	  chambers	  were	  detached	  from	  the	  slides,	  and	  30-­‐50μL	  of	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ProLong®	  Gold	  antifade	  reagent	  with	  DAPI	  from	  Life	  Technologies	  (Eugene,	  OR)	  was	  
added	  to	  each	  well.	  Slides	  were	  covered	  with	  a	  glass	  coverslip	  and	  allowed	  to	  dry	  
overnight.	  Microscopy	  was	  conducted	  using	  Zeiss	  AXIO	  Imager.M1	  at	  20X	  magnification.	  
The	  entirety	  of	  each	  slide	  was	  scanned	  and	  FFUs	  were	  counted	  (Figure	  2).	  Eight	  serial	  
dilutions	  of	  virus	  stock	  were	  tested	  to	  estimate	  the	  dilution	  for	  a	  final	  concentration	  of	  100	  
FFUs	  per	  well.	  
	  
This	  process	  was	  repeated	  for	  neutralization	  assays	  using	  approximately	  100	  FFUs	  of	  virus	  
per	  well	  with	  0.1,	  1.0,	  10.0,	  or,	  100.0μg/μL	  of	  neutralizing	  antibodies:	  1.6D	  or	  D11C,	  
described	  above.	  Neutralization	  by	  these	  antibodies	  was	  compared	  to	  a	  control	  antibody	  
C11,	  a	  human	  monoclonal	  antibody	  that	  binds	  a	  conserved	  region	  of	  the	  HIV1	  envelope	  
protein,	  Gp41	  (All	  antibodies	  were	  generously	  provided	  by	  Dr.	  John	  Schieffelin).	  Viruses	  
and	  antibodies	  were	  mixed	  together	  and	  allowed	  to	  incubate	  at	  room	  temperature	  for	  1	  
hour	  prior	  to	  infecting	  C6/36	  cells.	  Cells	  were	  infected	  with	  150μL	  of	  each	  solution	  and	  the	  
procedures	  followed	  as	  described	  above.	  Three	  biological	  replicates	  were	  performed	  for	  
each	  virus	  and	  antibody	  concentration.	  
	  
Rearing	  Mosquitoes	  
Aedes	  aegypti	  mosquito	  eggs	  were	  provided	  by	  the	  Connecticut	  Agricultural	  Experiment	  
Station.	  Eggs	  suspended	  on	  filter	  paper	  were	  allowed	  to	  hatch	  in	  a	  1%	  solution	  of	  yeast	  
liver	  extract	  in	  H2O.	  Containers	  were	  kept	  in	  a	  28°C	  incubator	  and	  fed	  with	  additional	  yeast	  
liver	  extract	  solution	  every	  1-­‐3	  days	  for	  a	  week.	  After	  one	  week	  pupae	  were	  transferred	  to	  
emergence	  containers	  on	  a	  daily	  basis	  until	  few	  larvae	  remained.	  Pupae	  were	  provided	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10%	  sucrose	  solution	  in	  deionized-­‐H2O	  on	  cotton	  balls	  during	  the	  emergence	  stage	  for	  
mosquito	  feeding.	  Approximately	  2-­‐3	  weeks	  after	  eggs	  were	  allowed	  to	  hatch	  mosquitoes	  
were	  aspirated,	  knocked-­‐down	  on	  ice,	  and	  females	  and	  males	  were	  separated.	  
Approximately	  70-­‐100	  females	  were	  held	  in	  each	  container	  with	  access	  to	  sucrose	  solution	  
until	  experiments,	  males	  were	  sacrificed.	  
	  
Mosquito	  Microinjections	  
Virus	  and	  antibody	  solutions	  comprised	  of	  100	  FFUs	  of	  DENV2	  mixed	  with	  0.05μg	  of	  
antibody,	  either	  1.6D	  or	  control	  antibody	  C11,	  brought	  up	  to	  20μL	  volume	  with	  PBS.	  The	  
solution	  was	  allowed	  to	  incubate	  at	  room	  temperature	  for	  1	  hour.	  Mosquitoes	  were	  
knocked-­‐down	  on	  ice	  and	  then	  injected	  in	  the	  thoracic	  cavity	  using	  the	  Nanoject	  II	  
Drummond	  Scientific	  (Broomall,	  PA).	  Each	  mosquito	  was	  injected	  with	  69nL	  at	  the	  fast	  
speed	  setting,	  46nL/second.	  After	  injection	  mosquitoes	  were	  placed	  back	  into	  containers	  
with	  10%	  sucrose	  and	  incubated	  for	  2	  days	  and	  4	  days.	  Mosquitoes	  were	  then	  knocked	  
down	  on	  ice	  and	  individually	  placed	  in	  2mL	  safety-­‐lock	  tubes	  with	  a	  bead	  and	  300μL	  of	  
PBS.	  Tubes	  were	  shaken	  in	  a	  bead	  beater	  for	  30	  seconds,	  25	  frequency	  and	  stored	  at	  -­‐80°C	  
until	  RNA	  analysis.	  
	  
Viral	  RNA	  Extraction	  and	  qRT-­‐PCR	  
RNA	  extraction	  was	  carried	  out	  using	  OMEGA	  bio-­‐tek	  Mag-­‐Bind®	  Viral	  DNA/RNA	  96	  kit	  
M6246-­‐03	  (Norcross,	  GA)	  solutions	  were	  made	  to	  manufacturer	  protocol.	  The	  96-­‐well	  plate	  
extraction	  machine	  King	  Fischer	  Flex	  by	  Thermo	  Scientific	  carried	  out	  extraction	  
automatically.	  BindIt	  Software	  3.3	  was	  programmed	  to:	  pick-­‐up	  tip	  plate,	  mix	  sample	  plate	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for	  Lysis	  binding	  for	  10	  minutes,	  bind	  beads,	  wash	  1	  minute	  in	  VHB	  buffer,	  bind	  beads,	  
wash	  1	  minute	  in	  SPR	  wash	  #1,	  bind	  beads,	  wash	  1	  minute	  in	  SPR	  wash	  #2,	  dry	  for	  45	  
seconds,	  mix	  5	  minutes	  for	  elution	  in	  50μL	  nuclease-­‐free	  H2O,	  and	  collect	  beads.	  
	  
Quantitative	  RT-­‐PCR	  was	  carried	  using	  previously	  characterized	  PCR	  primers	  and	  probe	  
that	  were	  verified	  for	  use	  on	  four	  Dengue	  virus	  serotypes	  (36).	  Solutions	  were	  made	  to	  
manufacturers	  instructions	  using	  BioRAD	  2x	  iTaq	  Universal	  Probes	  One-­‐Step	  Reaction	  Mix,	  
iScriptTM	  Reverse	  Transcriptase,	  in	  a	  20μL	  total	  volume.	  Primers	  purchased	  from	  IDT	  
include	  DENV1-­‐4	  qPCR	  Forward	  5’-­‐GCA	  TAT	  TGA	  CGC	  TGG	  GAR	  AGA	  –	  3’	  and	  DENV1-­‐3	  
qPCR	  Reverse	  5’-­‐TTC	  TGT	  GCC	  TGG	  AAT	  GAT	  GCT	  G-­‐3’,	  500nM	  of	  each	  primer	  was	  used	  per	  
reaction.	  The	  RT-­‐PCR	  probe	  was	  purchased	  from	  IDT:	  DEN1-­‐4	  qPCR	  5’-­‐6FAM-­‐CAG	  AGA	  TCC	  
TGC	  TGT	  C/3IABkFQ/-­‐3’,	  (6FAM	  is	  6-­‐carboxy	  fluorescein)	  250nM	  of	  probe	  per	  reaction.	  A	  
96-­‐well	  plate	  was	  loaded	  with	  15μL	  of	  solution	  and	  5μL	  of	  each	  RNA	  extracted	  sample,	  each	  
run	  was	  completed	  with	  DENV2	  standards	  at	  a	  concentration	  of	  103-­‐107	  in	  duplicate	  as	  well	  
as	  two	  RNA	  free	  wells.	  Plates	  were	  centrifuged	  to	  1500rpm	  for	  2	  minutes.	  The	  BIORAD	  
C1000	  Touch	  Thermal	  Cycler	  CFX96	  Real-­‐Time	  System	  (Hercules,	  CA)	  ran	  SYBR/FAM;	  
50°C,	  5	  minutes;	  95°C,	  20	  seconds;	  then	  40	  repeats	  of	  95°C,	  3	  seconds	  and	  60°C,	  30	  seconds	  
with	  photo.	  Data	  was	  configured	  on	  BIORAD	  CFX	  Manager	  3.1	  software	  for	  estimation	  of	  
viral	  load,	  genome	  equivalents	  per	  milliliter	  (GE/ml).	  
	  
Data	  Analysis	  
Data	  were	  analyzed	  in	  SAS	  9.3	  Statistical	  software	  (Cary,	  NC).	  Graphs	  were	  created	  in	  
Microsoft	  Excel	  (Redmond,	  WA)	  or	  GraphPad	  Prism	  6.0	  (La	  Jolla,	  CA).	  FFU	  assays	  were	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analyzed	  for	  1.6D	  and	  D11C	  as	  percent	  inhibition	  of	  the	  average	  C11	  FFU	  for	  each	  replicate	  
and	  then	  the	  average	  percent	  inhibition	  and	  standard	  deviation	  was	  calculated	  and	  
graphed	  in	  Excel.	  50%	  Inhibitory	  Concentration	  (IC50)	  was	  calculated	  from	  the	  linear	  
regression	  model	  best-­‐fit	  line	  in	  SAS	  constructed	  from	  the	  antibody	  log	  concentration	  as	  
the	  predictor	  variable	  and	  the	  percent	  inhibition	  as	  the	  response	  variable.	  
	  
The	  mean	  qRT-­‐PCR	  viral	  loads	  (GE/ml)	  for	  1.6D	  and	  C11	  antibody	  microinjected	  mosquito	  
groups	  were	  calculated	  and	  compared	  using	  a	  2-­‐sample	  2-­‐tailed	  t-­‐test	  in	  SAS.	  A	  p-­‐value	  less	  
than	  0.05	  was	  considered	  statistically	  significant,	  the	  Cochran	  method,	  which	  assumes	  


















The	  Flavivirus	  E	  protein	  nucleotide	  sequence	  phylogenetic	  tree	  is	  rooted	  with	  TBEV,	  a	  tick-­‐
borne	  Flavivirus,	  as	  an	  outgroup	  (Figure	  1B).	  YFV,	  which	  is	  transmitted	  by	  the	  same	  
mosquitoes	  as	  DENV,	  is	  more	  distantly	  related	  to	  the	  DENV	  cluster	  than	  WNV,	  a	  virus	  
transmitted	  by	  a	  different	  mosquito	  genus.	  Whereas	  the	  newly	  reemerging	  ZIKV,	  also	  
transmitted	  by	  the	  same	  mosquitoes	  as	  DENV,	  is	  more	  closely	  related	  than	  WNV.	  This	  
agrees	  with	  previous	  phylogenetic	  analyses	  (9,	  37).	  
	  
Fluorescent	  Focal	  Unit	  Assay	  
DENV2,	  DENV3,	  DENV4,	  and	  ZIKV	  readily	  infected	  C6/36	  cells	  and	  FFUs	  could	  be	  visualized	  
and	  counted	  as	  previously	  described	  (35)(Figure	  2).	  Broadly	  neutralizing	  human	  
antibodies	  1.6D	  and	  D11C	  inhibited	  DENV2,	  DENV3,	  and	  DENV4	  infections	  in	  C6/36	  cells	  in	  
a	  dose	  dependent	  manner	  (Figure	  3A	  and	  B,	  respectively).	  Inhibition	  was	  similar	  for	  all	  
three	  viruses	  and	  was	  similar	  between	  antibodies.	  Simple	  linear	  regression	  models	  were	  
constructed	  for	  the	  relationship	  between	  inhibition	  and	  antibody	  concentration,	  enabling	  
the	  calculation	  of	  the	  50%	  inhibitory	  concentration	  (Figure	  3C).	  IC50	  was	  lowest	  for	  D11C	  
against	  DENV3	  at	  0.07µg/ml	  and	  also	  low	  for	  1.6D	  at	  0.80µg/ml.	  For	  DENV2	  IC50	  of	  D11C	  
and	  1.6D	  were	  0.56µg/ml	  and	  0.77µg/ml	  respectively.	  DENV4	  IC50	  was	  slightly	  higher	  for	  
D11C	  and	  1.6D	  at	  1.56µg/ml	  and	  1.00µg/ml	  respectively.	  Neither	  antibody	  inhibited	  ZIKV	  
well.	  D11C	  showed	  a	  slightly	  more	  linear	  relationship	  and	  IC50	  of	  140.47µg/ml,	  whereas	  
1.6D	  had	  an	  IC50	  well	  above	  1000.00µg/ml,	  too	  far	  out	  of	  range	  for	  our	  tested	  




Viral	  loads	  were	  statistically	  significantly	  lower	  in	  Aedes	  aegypti	  mosquitoes	  injected	  with	  a	  
mixture	  of	  1.6D	  antibody	  and	  DENV2,	  compared	  to	  mosquitoes	  injected	  with	  the	  control	  
C11	  antibody	  (Table	  2).	  The	  log	  viral	  loads	  were	  compared	  because	  viral	  load	  ranged	  from	  
10	  to	  100,000	  GE/ml.	  At	  day	  2	  the	  mean	  log	  viral	  load	  was	  2.72	  ±	  0.54	  GE/ml	  for	  antibody	  
1.6D	  (N=86)	  and	  3.62	  ±	  0.58	  GE/ml	  for	  the	  control	  antibody	  (N=89).	  At	  day	  4	  the	  mean	  log	  
viral	  load	  was	  4.49	  ±	  0.64	  GE/ml	  for	  antibody	  1.6D	  (N=32)	  and	  5.00	  ±	  0.65	  GE/ml	  for	  the	  
control	  antibody	  (N=38).	  Day	  2	  viral	  loads	  are	  calculated	  from	  five	  independent	  replicates	  
of	  10-­‐20	  mosquitoes	  per	  replicate.	  Day	  4	  is	  calculated	  from	  three	  independent	  replicates	  of	  
7-­‐20	  mosquitoes	  per	  replicate.	  Statistical	  significance	  was	  maintained	  at	  day	  2	  and	  day	  4	  
post	  infection	  although	  the	  difference	  between	  the	  antibody	  and	  control	  viral	  loads	  
diminishes	  overtime	  (p<0.0001	  and	  p=0.0020	  respectively).	  There	  were	  negative	  samples	  
within	  both	  antibody	  groups,	  determined	  by	  comparing	  viral	  loads	  to	  negative	  mosquito	  
controls.	  Negatives	  among	  the	  control	  group	  may	  have	  been	  owing	  to	  physical	  injection	  
error	  but	  overall	  the	  decreased	  viral	  load	  consistently	  found	  for	  1.6D	  treated	  mosquitoes	  
















Antibodies	  1.6D	  and	  D11C	  are	  both	  promising	  candidates	  to	  inhibit	  Dengue	  virus	  infection	  
in	  Aedes	  mosquitoes.	  Results	  were	  consistent	  for	  DENV2,	  DENV3,	  and	  DENV4	  with	  50%	  
inhibitory	  concentration	  in	  C6/36	  cells	  ranging	  from	  0.07	  to	  1.56µg/ml.	  This	  is	  similar	  to	  
Costin	  et	  al.’s	  findings	  in	  mammalian	  cells	  for	  Dengue	  virus	  serotypes	  1-­‐4,	  where	  IC50	  was	  
0.2-­‐1.5µg/ml	  for	  antibody	  1.6D.	  However,	  while	  IC50	  of	  D11C	  ranged	  from	  1-­‐1.6µg/ml	  for	  
DENV1,	  DENV2,	  and	  DENV4	  they	  found	  weaker	  inhibition	  of	  DENV3,	  IC50	  of	  10.2µg/ml	  (1).	  
We	  found	  the	  greatest	  inhibition	  of	  DENV3	  with	  antibody	  D11C	  with	  an	  IC50	  of	  0.07µg/ml.	  
Perhaps	  this	  is	  indicative	  of	  conformational	  changes	  that	  allow	  greater	  antibody	  binding	  of	  
the	  target	  epitope	  in	  DENV3	  at	  lower	  temperatures.	  	  
	  
ZIKV	  infection	  was	  not	  inhibited	  by	  antibody	  1.6D	  or	  D11C	  in	  our	  FFU	  assay.	  This	  is	  
somewhat	  surprising	  given	  the	  relatedness	  between	  the	  ZIKV	  E	  protein,	  particularly	  the	  
fusion	  loop,	  and	  that	  of	  DENV.	  These	  antibodies	  were	  previously	  shown	  to	  weakly	  inhibit	  
YFV	  and	  more	  robustly	  inhibit	  WNV	  in	  mammalian	  cells.	  WNV	  is	  more	  closely	  related	  to	  
DENV	  than	  YFV,	  and	  ZIKV	  is	  more	  closely	  related	  still.	  Potentially	  other	  differences	  in	  the	  
ZIKV	  E	  protein	  amino	  acid	  sequence	  results	  in	  a	  quaternary	  structure	  that	  the	  antibody	  
does	  not	  recognize	  or	  bind	  as	  effectively.	  The	  conserved	  residues	  101W	  and	  109G	  in	  DENV	  
have	  a	  homologous	  region	  in	  ZIKV	  although	  there	  are	  other	  stretches	  of	  amino	  acids	  
missing	  in	  the	  ZIKV	  E	  protein.	  The	  truncation	  of	  this	  protein	  may	  form	  a	  structure	  
dissimilar	  enough	  to	  make	  binding	  less	  efficient.	  Given	  the	  current	  public	  health	  
importance	  of	  ZIKV	  an	  alternative	  antibody	  may	  be	  more	  appropriate	  for	  use	  in	  areas	  
endemic	  with	  both	  Dengue	  and	  Zika.	  Nevertheless,	  DENV	  remains	  the	  leading	  cause	  of	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mosquito-­‐borne	  viral	  disease	  and	  this	  technology	  is	  still	  very	  valuable	  for	  preventing	  
transmission.	  Within	  the	  mosquito,	  human	  antibodies	  in	  combination	  with	  natural	  
mosquito	  immunity	  may	  be	  sufficient	  to	  significantly	  reduce	  mosquito	  infection	  and	  
transmission.	  
	  
Results	  from	  our	  microinjection	  experiments	  suggest	  that	  the	  1.6D	  antibody	  consistently	  
neutralizes	  DENV2	  and	  inhibits	  the	  infection	  of	  Aedes	  aegypti	  mosquitoes.	  C6/36	  cells	  
provided	  valuable	  information	  about	  neutralization	  and	  inhibitory	  concentration	  in	  insect	  
cells.	  However,	  these	  results	  were	  strengthened	  by	  the	  additional	  evidence	  that	  
neutralization	  is	  maintained	  within	  living	  mosquitoes.	  By	  examining	  the	  effects	  at	  day	  2	  
and	  day	  4	  we	  are	  confident	  that	  mosquitoes	  were	  appropriately	  injected	  with	  virus	  and	  
antibody	  solutions	  for	  both	  the	  1.6D	  antibody	  and	  the	  control	  and	  the	  decrease	  in	  viral	  load	  
is	  a	  demonstration	  of	  neutralization.	  Overtime	  the	  viruses	  that	  are	  able	  to	  infect	  the	  
mosquito	  replicate	  and	  diminish	  the	  difference	  in	  viral	  loads.	  If	  an	  appropriate	  
concentration	  of	  antibody	  can	  be	  secreted	  into	  the	  mosquito	  midgut	  at	  the	  time	  of	  taking	  an	  
infected	  blood	  meal,	  antibody	  neutralization	  in	  combination	  with	  mosquito	  immunity	  could	  
suppress	  mosquito	  cell	  infection.	  Additionally,	  virus	  must	  spread	  from	  the	  midgut	  to	  the	  
salivary	  glands	  in	  order	  to	  be	  transmitted	  to	  a	  new	  human	  host.	  Antibodies	  could	  be	  
secreted	  throughout	  this	  pathway	  as	  was	  achieved	  in	  mosquitoes	  with	  anti-­‐malaria	  
antibodies.	  This	  strategy	  successfully	  prevented	  the	  infectious	  form	  of	  malaria	  parasites	  
from	  reaching	  the	  mosquito	  salivary	  glands	  (27).	  The	  true	  test	  of	  this	  new	  technology	  will	  
not	  simply	  be	  a	  reduction	  in	  mosquito	  infections	  but	  a	  reduction	  in	  mosquito	  competence	  





Unfortunately	  we	  were	  unable	  to	  verify	  inhibition	  of	  DENV1	  in	  our	  FFU	  assay	  owing	  to	  
challenges	  faced	  in	  our	  assay	  development,	  and	  not	  related	  to	  the	  antibody-­‐virus	  
interactions.	  The	  strain	  of	  DENV1	  tested	  caused	  so	  much	  C6/36	  cell	  death	  it	  was	  impossible	  
to	  visualize	  fluorescent	  foci	  or	  count	  foci	  accurately.	  Previous	  studies	  of	  these	  antibodies	  in	  
human	  cells	  showed	  strong	  inhibition	  of	  DENV1	  at	  par	  or	  better	  than	  other	  serotypes.	  
	  
The	  eventual	  goal	  of	  this	  research	  is	  to	  demonstrate	  the	  efficacy	  of	  inhibiting	  mosquito	  
infection	  that	  ultimately	  reduces	  viral	  transmission.	  We	  showed	  antibodies	  could	  reduce	  
viral	  load	  in	  mosquito	  cells	  and	  live	  mosquitoes	  but	  further	  work	  needs	  to	  show	  that	  this	  
translates	  to	  reduced	  viral	  infection	  following	  a	  blood	  meal	  and	  that	  the	  reduction	  is	  
sufficient	  to	  reduce	  viral	  transmission.	  Upon	  membrane	  blood	  feeding	  of	  Aedes	  aegypti	  
mosquitoes	  with	  DENV2	  less	  than	  40%	  of	  mosquitoes	  became	  infected.	  With	  limited	  
antibody	  stock	  and	  with	  antibody	  at	  a	  concentration	  of	  approximately	  1mg/ml	  it	  was	  not	  
feasible	  to	  produce	  solutions	  of	  virus	  and	  antibody	  where	  both	  the	  control	  mosquitoes	  
became	  infected	  and	  the	  antibody	  concentration	  reflected	  the	  inhibitory	  concentrations	  
determined	  in	  FFU	  assays.	  
	  
Future	  Directions	  
This	  study	  demonstrates	  that	  human	  antibodies	  can	  neutralize	  viruses	  at	  lower	  
temperatures	  typical	  of	  mosquitoes	  and	  neutralization	  significantly	  decreases	  mosquito	  
infection.	  Further	  development	  of	  a	  more	  sensitive	  assay	  to	  detect	  virus	  in	  mosquitoes	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could	  help	  determine	  whether	  this	  strategy	  would	  be	  biologically	  feasible	  and	  impactful	  in	  
a	  mosquito	  population.	  
	  
The	  development	  of	  a	  transgenic	  Aedes	  aegypti	  line	  could	  then	  be	  created	  that	  allows	  for	  
viral-­‐antibody	  interactions	  to	  occur	  within	  the	  mosquito	  over	  the	  course	  of	  a	  natural	  virus	  
infection.	  Given	  the	  advancement	  of	  gene	  drive,	  these	  antibodies	  could	  be	  propagated	  
throughout	  Aedes	  populations	  and	  reduce	  the	  population	  of	  Dengue	  virus	  transmitting	  
mosquitoes	  (38,	  39).	  Additional	  work	  should	  be	  considered	  that	  would	  extend	  
neutralization	  to	  Zika	  and	  Yellow	  Fever	  virus,	  two	  prominent	  and	  life-­‐threatening	  viral	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Figure	  1.	  (A)	  Genome	  Organization	  of	  Flaviviruses	  (9).	  Composed	  of	  the	  structural	  
proteins:	  capsid	  (C),	  premembrane	  (PrM),	  and	  envelope	  (E)	  proteins	  followed	  by	  enzymes	  
utilized	  for	  virus	  replication	  and	  transmission	  (1).	  (B)	  Flavivirus	  phylogenetic	  tree	  of	  E	  
protein	  nucleotide	  sequences	  accessed	  from	  GenBank.	  Clustal	  W	  alignment	  conducted	  in	  
MegAlign,	  scale	  is	  percentage	  of	  genetic	  difference;	  Tick-­‐Borne	  Encephalitis	  Virus	  (TBEV)	  is	  
a	  tick-­‐borne	  Flavivirus.	  (C)	  Highly	  conserved	  amino	  acid	  sequence	  of	  the	  E	  protein	  fusion	  
loop,	  identical	  in	  Dengue	  viruses	  and	  Zika	  virus	  used	  in	  phylogenetic	  alignment.	  
Highlighted	  are	  two	  amino	  acids	  (101W	  and	  109G)	  mapped	  to	  be	  important	  in	  1.6D	  and	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Table	  1.	  Flaviviruses	  used	  in	  experiments.	  Emphasis	  was	  placed	  on	  viruses	  with	  low	  
passage	  in	  either	  mammalian	  or	  insect	  cell	  lines.	  Dengue	  virus	  3	  and	  4,	  and	  Zika	  virus	  came	  
from	  the	  Yale	  Arbovirus	  Research	  Unit	  collection.	  C6/36	  are	  an	  Aedes	  albopictus	  mosquito	  
cell	  line,	  Vero	  are	  an	  African	  green	  monkey	  kidney	  epithelial	  cell	  line.	  
	  
Virus	   Location/	  
Year	  
Cell	  Passage	   Strain	   GenBank	  
Accession	  no.	  
Dengue	  type	  2	   Jamaica/1983	   NA	   1409	   M20558.1	  
	  
Dengue	  type	  3	   Thailand/1989	   C6/36	  (X2)	   -­‐	   -­‐	  
	  
Dengue	  type	  4	   El	  Salvador/1989	   C6/36	  (X2)	   -­‐	   -­‐	  
	  


































Figure	  2.	  Fluorescent	  Focus	  Unit	  Assays,	  microscopy	  images	  taken	  on	  Zeiss	  AXIO	  
Imager.M1,	  20X	  magnification.	  Examples	  of	  Dengue	  virus	  2	  and	  Zika	  virus	  foci	  in	  C6/36	  
cells	  compared	  to	  a	  control	  that	  was	  not	  infected	  with	  virus.	  Virus	  stained	  with	  primary	  
antibody,	  PierceTM	  FlaviVs	  Envelope	  Antibody	  (FE1),	  Thermo	  Scientific,	  which	  binds	  the	  
Flavivirus	  envelope,	  and	  was	  effective	  for	  all	  viruses	  tested	  in	  our	  experiments.	  Secondary	  
antibody	  purchased	  from	  Life	  Technologies,	  goat	  anti-­‐mouse	  Alexa	  Fluor	  488,	  was	  





















Figure	  3.	  Dengue	  virus	  infection	  percent	  inhibition,	  fluorescent	  focus	  unit	  assays	  in	  C6/36	  
Aedes	  albopictus	  cells.	  (A)	  Antibody	  1.6D.	  (B)	  Antibody	  D11C.	  The	  error	  bars	  signify	  
standard	  deviations.	  (C)	  Linear	  regression	  best-­‐fit	  model	  with	  log	  base	  10	  transformed	  
antibody	  concentration.	  50%	  inhibitory	  antibody	  concentration	  (IC50)	  calculated	  from	  the	  












































































DENV2	   Y	  =	  10.36x	  +	  52.74	   0.77	  
DENV3	   Y	  =	  8.00x	  +	  51.82	   0.80	  
DENV4	  
ZIKV	  
Y	  =	  10.21x	  +	  49.95	  





DENV2	   Y	  =	  10.09x	  +	  55.94	   0.56	  
DENV3	   Y	  =	  6.36x	  +	  66.58	   0.07	  
DENV4	  
ZIKV	  
Y	  =	  10.40x	  +	  45.40	  


















Figure	  4.	  (A)	  Decreased	  DENV2	  viral	  load	  with	  the	  DENV	  neutralizing	  antibody	  1.6D	  
compared	  to	  the	  C11	  control	  antibody.	  Infection	  in	  Aedes	  aegypti	  mosquitoes	  carried	  out	  
through	  69nL	  microinjections	  of	  the	  thoracic	  cavity,	  100	  FFUs	  of	  DENV2	  and	  0.05µg	  
antibody	  per	  injection.	  Mosquitoes	  sacrificed	  2	  days	  (five	  biological	  replicates	  of	  10-­‐20	  
mosquitoes	  per	  replicate)	  and	  4	  days	  (3	  biological	  replicates	  of	  7-­‐20	  mosquitoes	  per	  
replicate)	  post	  infection	  (dpi).	  Mean	  and	  Standard	  Deviation	  (SD)	  of	  the	  log	  base	  10	  viral	  
load	  (GE/ml)	  were	  calculated	  and	  compared	  for	  each	  day.	  P-­‐values	  were	  calculated	  as	  two-­‐
tailed	  probabilities	  of	  a	  t	  distribution	  in	  SAS;	  Cochran	  method	  assumes	  unequal	  variance.	  






	   Antibody	   N	   Mean	  ±	  	  SD	   Minimum	   Maximum	   P-­‐value	  
Day	  2	   1.6D	   86	   2.72	  ±	  0.54	   1.43	   4.11	   <0.0001	  
C11	   89	   3.62	  ±	  0.58	   1.81	   4.68	   	  
Day	  4	   1.6D	   32	   4.49	  ±	  0.64	   2.02	   5.44	   	  	  0.0020	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